BioChem Immunosystems aims to broaden UK portfolio:
This article was originally published in Clinica
BioChem Immunosystems UK - previously Serono Diagnostics - aims to broaden its portfolio following acquisition by BioChem Immunosystems (Canada). The company currently sells monoclonal antibodies and makes hybridomas under licence agreements. Cell lines include AFP, CEA, insulin, TSH, FSH, hGC, LH, prolactin and phencyclidine.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.